Cardio-Oncology (Oct 2020)

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma

  • Nway Le Ko Ko,
  • Nareg Minaskeian,
  • Hicham Z. El Masry

DOI
https://doi.org/10.1186/s40959-020-00077-5
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 4

Abstract

Read online

Abstract This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.

Keywords